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Abstract
Introduction: This study aimed to investigate whether hydroxynonenal (HNE) depletion is responsible for the
switch from cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) to 5-lipoxygenase-
activating protein (FLAP) and 5-lipoxygenase (5-LOX).
Methods: For COX-2 and mPGES-1 studies, human osteoarthritic chondrocytes were stimulated at different
incubation times (up to 24 hours) with a single or repetitive addition of 10 μM HNE to the cultures at 2-hour
intervals, up to 14 hours. For 5-LOX and FLAP studies, cells were treated with a single addition of 10 μM HNE for
24 hours, 48 hours, and 72 hours in the presence or absence of naproxen (a nonspecific COX-2 inhibitor) or
antibody anti-transforming growth factor-beta 1 (TGF-b1). The protein levels of COX-2, mPGES-1 and early growth
response factor-1 (Egr-1) transcription factor were evaluated by western blot, and those of prostaglandin E2 (PGE2),
leukotriene B4 (LTB4) and TGF-b1 were determined with commercial kits. The levels of mPGES-1, FLAP and 5-LOX
mRNA were measured by real-time RT-PCR. Transient transfection was performed to determine promoter activities
of mPGES-1 and 5-LOX.
Results: Single addition of 10 μM HNE to cultured chondrocytes induced PGE2 release as well as COX-2 and
mPGES-1 expression at the protein and mRNA levels, with a plateau reached respectively at 8 and 16 hours of
incubation, followed by a subsequent decline. However, repeated treatments with HNE prevented the decline of
COX-2 and mPGES-1 expression that occurred with a single aldehyde addition. HNE induced mPGES-1 promoter
activity, possibly through transcription factor Egr-1 activation. After 48 hours, when COX-2 expression decreased,
the LTB4 level rose through 5-LOX and FLAP upregulation. The addition of naproxen to cultured chondrocytes
revealed that FLAP and 5-LOX regulation by HNE required PGE2 production. Furthermore, our data showed that
HNE significantly induced TGF-b1 production. The addition of anti-TGF-b1 antibody reduced HNE-induced 5-LOX
and FLAP expression by 40%, indicating the partial involvement of a TGF-b1-dependent mechanism.
Conclusions: Our data demonstrate that the shunt to the FLAP and 5-LOX pathway in HNE-induced human
osteoarthritic chondrocytes is attributed to COX-2 and mPGES-1 inhibition, probably due to HNE depletion. PGE2
and TGF-b1 are suggested to be involved in this regulation.
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Osteoarthritis (OA) is a degenerative joint disease with
abnormal alterations in the structure, composition and
function of articular tissues. Morphological changes in
OA include cartilage destruction, osteophyte formation
and synovial inflammation [1]. It is believed that over-
produced proinflammatory cytokines, such as IL-1b and
TNFa, are involved in the pathogenesis of OA by metal-
loproteinase (MMP) upregulation and collagen downre-
gulation. Moreover, IL-1b and TNFa stimulate the
production of prostaglandins, such as prostaglandin E2
(PGE2), whose roles in the inflammatory process and
proteoglycan degradation in human OA cartilage have
been reported [2].
PGE2, a major prostaglandin produced via arachido-
nic acid (AA) metabolism, is involved in many physio-
logical events, such as cell growth, immune regulation,
inflammation and arthritis [3]. Cyclooxygenase (COX)
and prostaglandin E2 synthase (PGES) are key enzymes
for PGE2 biosynthesis under inflammatory conditions.
COX-1 and COX-2 convert AA into prostaglandin H2,
which is subsequently converted to PGE2 by PGES.
Among all forms of PGES, microsomal PGES-1
(mPGES-1) has been studied the most because of its
inducible characteristic and collaboration with induci-
b l eC O X - 2 ,l e a d i n gt oP G E 2 production. It has been
shown that mPGES-1 expression is upregulated in ani-
mal models of rheumatoid arthritis and in patients suf-
fering from OA [4,5] and is downregulated by anti-
inflammatory drugs [6,7]. mPGES-1 expression is regu-
lated by several transcription factors, such as early
growth response-1 (Egr-1) and NF-B, in different cell
types [8,9].
Leukotrienes, other end-products of AA metabolism,
are potent mediators of inflammation that increase the
activation, migration and adhesion of immune cells [10].
In particular, leukotriene B4 (LTB4) promotes the pro-
duction and release of proinflammatory cytokines from
synovial membranes, drawing more attention to its role
in OA. Clinical investigations have revealed that long-
term COX-2 inhibition causes a switch to the 5-lipoxy-
genase (5-LOX) pathway, leading to LTB4 production
[11]. It is now clear that prostaglandins and leukotrienes
have additional outcomes; blocking the production of
these mediators might therefore have synergistic effects
and achieve optimal anti-inflammatory activity [3].
Functional 5-LOX requires binding to 5-lipoxygenase-
activating protein (FLAP), which helps 5-LOX binding
to AA at the nuclear membrane and enhances the effi-
ciency of leukotriene synthesis [12]. 5-LOX gene expres-
sion at the transcriptional level is regulated by several
transcription factors, such as smad3/4 and vitamin D
receptors [13,14].
Reactive oxygen species produced inside the joints also
are associated with the pathogenesis of OA [15]. They
induce lipid peroxidation of membrane polyunsaturated
fatty acids, eliciting the production of aldehydes from
AA [16,17]. 4-Hydroxynonenal (HNE) has been found
to be the predominantly produced and most reactive
aldehyde in OA articular tissues [18]. We recently
reported, for the first time, that free HNE induces carti-
lage degradation in isolated OA chondrocytes and alters
the cellular phenotype of OA osteoblasts. These
responses are mediated by the modulation of a panoply
of signaling pathways, including mitogen-activated pro-
tein kinases and NF-B [18-20]. By binding to proteins,
HNE activates MMP-13 and increases the susceptibility
of type II collagen to proteolytic cleavage by MMP-13
[18]. In another study, we demonstrated that HNE con-
tributes to inflammatory responses in OA chondrocytes
through the transcriptional upregulation of COX-2 via
the p38 mitogen-activated protein kinase signaling path-
way. We observed that HNE-induced COX-2 declines
rapidly after 8 hours of incubation. HNE most probably
represents one of the main lipid peroxidation products
that can modulate physiological as well as pathological
processes, as depicted beautifully in a recent, dedicated
review [21].
The objectives of the present project were to investi-
gate whether COX-2 and mPGES-1 downregulation,
attributed to HNE depletion, is responsible for the
switch from COX-2 and mPGES-1 to 5-LOX and FLAP,
and to elucidate the molecular mechanisms underlying
their expression in HNE-treated human OA
chondrocytes.
Materials and methods
Tissue samples
Postsurgery, discarded human OA articular cartilage was
obtained from OA patients (mean ± standard deviation
age, 67 ± 9 years) who underwent total knee arthro-
plasty. Informed consent had been obtained from
patients with OA for the use of their tissues for research
purposes. All patients were evaluated by rheumatologists
who followed American College of Rheumatology cri-
teria [22]. The Clinical Research Ethics Committee of
the Hôpital du Sacré-Cœur de Montréal, including clini-
cians, researchers and jurists, approved the study proto-
col and the use of human articular tissues.
Chondrocyte culture
OA cartilage (femoral condyles and tibial plateaus) was
obtained under aseptic conditions and carefully dis-
sected from the underlying bone in each specimen [23].
OA chondrocytes were extracted by sequential enzy-
matic digestion with 1 mg/ml pronase (Sigma, Oakville,
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type IV collagenase (Sigma) for 6 hours in DMEM (Invi-
trogen, Burlington, ON, Canada) supplemented with
10% heat-inactivated fetal bovine serum (Invitrogen),
100 units/ml penicillin and 100 μg/ml streptomycin
(Invitrogen). The cells were seeded at high density in
culture flasks at 37°C in a humidified atmosphere of 5%
CO2/95% air until they were confluent and ready for the
experiments. First-passage cells were employed to
ensure their phenotype and were seeded at 10
5 cells/
cm
2 in culture tissue plates. The DMEM containing 2%
fetal bovine serum and antibiotics was replaced 24
hours before the experiments were performed in this
medium with the factors under study for different incu-
bation time periods.
For COX-2 and mPGES-1 studies (up to 24 hours),
chondrocytes were treated with a single addition of 10
μM HNE or with repeated treatments by adding 10 μM
HNE to the cultures at 0, 2, 4, 6, 8, 10, 12 and 14 hours.
For 5-LOX and FLAP studies (up to 72 hours), cells
were treated with a single addition of 10 μMH N Ei n
t h ep r e s e n c eo ra b s e n c eo f5 0μMn a p r o x e no r1 0 0μg/
ml anti-transforming growth factor-beta 1 (TGFb1).
Protein detection by western blotting
Twenty micrograms of total proteins from chondrocyte
lysates treated with HNE under the indicated conditions
were loaded for discontinuous 4 to 12% SDS-PAGE.
Protein transfer, immunodetection and semiquantitative
measurements were performed as described previously
[18]. The primary antibodies were rabbit anti-COX-2
(Cayman Chemical, Hornby, ON, Canada), anti-mPGES-
1 (Cayman Chemical), anti-b-actin (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and anti-Egr-1 (Santa
Cruz Biotechnology). After serial washes, primary anti-
bodies were detected by goat anti-rabbit IgG conjugated
to horseradish peroxidase (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA). Immunoreac-
tive proteins were detected with SuperSignal blotting
substrate (Pierce Biotechnology, Inc., Rockford, IL, USA)
and were exposed to clear-blue X-ray film (Pierce).
RNA extraction and RT-PCR
Total RNA was isolated with TRIzol reagent according
to the manufacturer’s instructions. RNA was quantitated
with the RiboGreen RNA quantitation kit (Molecular
Probes, Eugene, OR, USA), dissolved in diethylpyrocar-
bonate-treated H2O ,a n ds t o r e da t- 8 0 ° Cu n t i lu s e .O n e
microgram of total RNA was reverse-transcribed with
M o l o n e ym u r i n el e u k e m i av i r u sr e v e r s et r a n s c r i p t a s e
(Fermentas, Burlington, ON, Canada), as detailed in the
manufacturer’s guidelines. One-fiftieth of the reverse
transcriptase reaction product was analyzed by tradi-
tional PCR or by real-time quantitative PCR. The
following sense and antisense specific primers (Bio-
Corp, Inc., Montreal, QC, Canada), were tested: human
mPGES-1, 5’-GAA GAA GGC CTT TGC CAA C-3’
(sense) and 5’-GGA AGA CCA GGA AGT GCA TC-3’
(antisense); human 5-LOX, 5’-CTG TTC CTG GGC
ATG TAC CC-3’ (sense) and 5’-GAC ATC TAT CAG
TGG TCG TG-3’ (antisense); human FLAP, 5’-AAT
GGG AGG AGC TTC CAG AG-3’ (sense) and 5’-ACC
AAC CCC ATA TTC AGC AG-3’ (antisense); and
human GAPDH, 5’-CAG AAC ATC ATC CCT GCC
TCT-3’ (sense) and 5’-GCT TGA CAA AGT GGT CGT
TGA G-3’ (antisense).
Quantitative PCR analysis was performed in a total
volume of 50 μl containing template DNA, 200 nM
sense and antisense primers, 25 μl SYBR Green Master
Mix (Qiagen, Mississauga, ON, Canada), and 0.5 units
uracil-N-glycosylase (Epicentre Technologies, Madison,
WI, USA). After incubation at 50°C for 2 minutes (ura-
cil-N-glycosylase reaction) and at 95°C for 10 minutes
(uracil-N-glycosylase inactivation and activation of
AmpliTaq Gold enzyme), the mixtures were subjected
to 40 amplification cycles (15 seconds at 95°C for dena-
turation and 1 minute for annealing and extension at
60°C). Incorporation of SYBR Green dye into the PCR
products was monitored in real time with a Mx3000
real-time PCR system (Stratagene, La Jolla, CA, USA),
to determine the threshold cycle (Ct) at which exponen-
tial amplification of PCR products begins. After PCR,
dissociation curves were generated with one peak, indi-
cating amplification specificity. A Ct value was obtained
from each amplification curve with the software pro-
vided by the manufacturer (Stratagene).
Relative mRNA expression in chondrocytes was quan-
tified according to the ΔΔCt method, as detailed in the
manufacturer’s guidelines (Stratagene). A ΔCt value was
first calculated by subtracting the Ct value for the
housekeeping gene GAPDH from the Ct value for each
sample. A ΔΔCt value was then calculated by subtract-
ing the ΔCt v a l u ef o rt h ec o n t r o l s( u n s t i m u l a t e dc e l l s )
from the ΔCt value for each treatment. Fold changes
compared with the controls were then determined by 2
-
ΔΔC
t. Each PCR generated only the expected specific
amplicon, as shown by melting temperature profiles of
the final product and gel electrophoresis of the test
PCRs. Each PCR was performed in triplicate on two
separate occasions for each independent experiment.
Prostaglandin E2, leukotriene B4 and TGF-b1 enzyme
immunoassay
After incubation, the culture medium from cultured OA
chondrocytes was collected and the PGE2,L T B 4 and
TGF-b1 levels were measured with specific commercial
kits from Cayman Chemical and R&D Systems (Minnea-
polis, MN, USA), according to the manufacturer’s
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pg/ml, respectively. All assays were performed in
duplicate.
Plasmids and transient transfection
The human mPGES-1 promoter construct (-538/-28)
was a gift from Dr Terry J. Smith (University of Califor-
nia, Los Angeles, CA, USA) [24]. The pEgr-1Mutx3-TK-
Luc reporter construct was generously provided by Dr
Yuqing E. Chen (Morehouse School of Medicine,
Atlanta, GA, USA) [25]. The 5-LOX promoter construct
was kindly donated by Dr Dieter Steinhilber (University
of Frankfurt, Frankfurt, Germany).
Subconfluent human OA chondrocytes were transi-
ently transfected in 12-well cluster plates with lipofecta-
mine 2000™ reagents (Invitrogen Life Technology, Inc.),
according to the manufacturer’s protocol. Briefly, trans-
fections were conducted for 6 hours with DNA lipofec-
tamine complexes containing 10 μl lipofectamine
reagent, 2 μgD N Ap l a s m i da n d0 . 5μgp C M V - b-galac-
tosidase (as a transfection efficiency control). In cotrans-
fection experiments the amount of transfected DNA was
kept constant using a corresponding empty vector.
Using the method of Howcroft and colleagues [26], the
transfection efficiency was measured and the average
rate of transfected cells was 48%. After washing, the
cells were incubated for different incubation periods in
the presence or absence of 10 μM HNE (single addition)
in fresh DMEM culture medium containing 2% fetal
bovine serum in a humidified atmosphere of 95% air/5%
CO2 at 37°C. Luciferase activity was determined in cell
lysate with commercially available kits (Luciferase assay
system; Promega Corporation, Madison, WI, USA). The
data were normalized to the b-galactosidase level, which
was quantified in cell lysate by a specific ELISA (Roche
Applied Science, Laval, QC, Canada).
Statistical analysis
All quantitative results were calculated as the mean ±
standard error of the mean. The data were assessed by
Student’s unpaired t test. P < 0.05 was considered statis-
tically significant.
Results
Single or repeated HNE treatments regulate differently
PGE2 release and COX-2 protein expression
As described in our previous report [20], COX-2 protein
and mRNA expression decreased gradually after 8 hours
of chondrocyte incubation with single addition of 10
μM HNE. To examine whether this reduction is attribu-
ted to HNE depletion, cells were stimulated with either
single or repeated 10 μM HNE treatments for different
incubation periods (0 to 24 hours, n = 4 independent
experiments) as described in Materials and methods.
Single treatment of chondrocytes with 10 μMH N E
showed an increase in COX-2 protein expression and
PGE2 release within 2 hours and plateaued at 8 hours
of incubation, before declining at 16 hours and 24
hours (Figure 1a, b). PGE2 a n dC O X - 2r e a c h e dm a x i -
mum levels of 157.5 ± 33 ng/10
5 cells and 340% of
control values, respectively (P < 0.001). In experiments
where the cells were stimulated with repetitive addi-
tion of 10 μMH N E ,h o w e v e r ,P G E 2 release and COX-
2 protein expression were enhanced after 4 hours of
incubation, with maximu mv a l u e so b t a i n e da t2 4
hours (Figure 1c, d). Maximum PGE2 and COX-2
values were 210 ± 29 ng/10
5 cells and 400% of control
values, respectively (P < 0.001). Single or repeated
treatments with 10 μM HNE did not induce either
toxic or apoptotic phenomena in chondrocytes (data
not included).
These data suggest for the first time that repeated
treatments at 2-hour intervals with 10 μMH N Ea r e
essential to maintain the protein expression of COX-2
up to 24 hours.
Induction of mPGES-1 protein and mRNA expression by
single or repeated HNE treatments
To gain insights into the role of HNE in the mechanism
underlying the production of PGE2 we evaluated its
effect on the protein and mRNA expression of mPGES-
1, an inducible form of PGES involved in the terminal
step of PGE2 synthesis. Human OA chondrocytes were
treated once or several times for different incubation
periods as described in Materials and methods (n =4
independent experiments).
Treatment of chondrocytes with single addition of 10
μM HNE to cultures significantly increased mPGES-1
protein and mRNA levels, which plateaued at 16 hours
but then declined at 24 hours (Figure 2a, c). mPGES-1
protein and mRNA reached maximum levels of 230 and
220% of control values, respectively (P < 0.01). Repeated
treatments at 2-hour intervals with 10 μMH N E ,h o w -
ever, enhanced mPGES-1 protein and mRNA levels and
plateaued at 24 hours (Figure 2b, c). The maximum
levels of mPGES-1 protein and mRNA were 400 and
300% of the controls, respectively (P < 0.001).
Similar to COX-2, our data indicate that the main-
tained mPGES-1 protein and mRNA expression might
be linked to repetitive treatments with HNE.
HNE-induced mPGES-1 and 3xEgr-1 binding site promoter
activities
In our previous report, we reported that HNE induced
COX-2 transcription through ATF-2/CREB-1 transacti-
vation [20]. In the present study, we further examined
whether HNE induced mPGES-1 at a transcriptional
level through Egr-1 transactivation.
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mRNA levels can be ascribed to the regulation in pro-
moter activity, chondrocytes were transiently transfected
with human mPGES-1 promoter-luciferase reporter
genes (n = 6 independent experiments) and then treated
with single addition of 10 μM HNE to all wells except
the controls. As shown in Figure 3a, HNE induced
mPGES-1 promoter activity in a time-dependent incre-
ment. Maximum promoter activity was 331% at 16
hours compared with the control (P < 0.001).
Secondly, we analyzed the effect of HNE on the tran-
scriptional activation of a synthetic luciferase reporter con-
struct containing three tandem repeats of the putative
Egr-1 binding sequence, pEgr-1x3-TK-Luc. The transcrip-
tion factor Egr-1 is believed to mediate the induction of a
h o s to ft a r g e tg e n e ss u c ha sm P G E S - 1 ,a ss u g g e s t e db y
Cheng and colleagues [8]. As seen in Figure 3b, HNE
increased the luciferase activity of the above construct,
and this activation was time dependent. Maximum pro-
moter activity reached 450% at 16 hours compared with
the controls (P < 0.001). Western blot analysis revealed
that single treatment with 10 μM HNE induced Egr-1 pro-
tein expression by 280% compared with untreated cells
after 16 hours of incubation (Figure 3c).
Collectively, these data suggest that Egr-1 may be one
of the transcription factors involved in HNE-induced
mPGES-1 promoter activity.
HNE-induced LTB4 release through 5-LOX and FLAP
upregulation
In the next series of experiments, we further investi-
gated whether the decrease of COX-2 expression in
treated chondrocytes with single addition of 10 μM
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Figure 1 Single or repeated treatments with hydroxynonenal regulate differently prostaglandin E2 release and cyclooxygenase-2
expression. Human osteoarthritis chondrocytes were treated for different periods of incubation: (a), (b) with a single addition of 10 μM4 -
hydroxynonenal (HNE), or (c), (d) with repeated treatments by adding 10 μM HNE to the cultures at 2-hour intervals up to 14 hours. (a), (c)
Prostaglandin E2 (PGE2) concentrations were measured by enzyme immunoassay commercial kit. (b), (d) Cyclooxygenase-2 (COX-2) protein
expression was analyzed by western blotting. Data are means ± standard errors of the mean, n = 4, expressed as percentages of untreated cells.
Student’s unpaired t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 2 Hydroxynonenal-induced microsomal prostaglandin E2 synthase-1 protein and mRNA expression in human osteoarthritis
chondrocytes. Cells were stimulated (a), (c) with 10 μM 4-hydroxynonenal (HNE) once or (b), (c) repeatedly with 10 μM HNE every 2 hours for
different incubation periods, as indicated above. Microsomal prostaglandin E2 synthase-1 (mPGES-1) (a), (b) protein and (c) mRNA were
measured respectively by western blotting and real-time RT-PCR. Data are means ± standard errors of the mean, n = 4, expressed as
percentages of untreated cells. Student’s unpaired t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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normalized to b-galactosidase activity. (c) Osteoarthritis chondrocytes were treated with 10 μM HNE at increasing time of incubation and then
Egr-1 protein expression was evaluated in the cellular extract by western blot. Data are means ± standard errors of the mean, n = 6, expressed
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tion. LTB4 is a potent chemoattractant and stimulator of
inflammation [27] and probably contributes, along with
other factors, to the upregulation of the synthesis of
other catabolic factors involved in the pathophysiology
of OA [28]. Human OA chondrocytes (n = 5 indepen-
dent experiments) were treated for different incubation
periods with single addition of 10 μM HNE to all wells
except the controls. HNE-induced changes in the LTB4
level and in 5-LOX and FLAP mRNA expression and
were evaluated respectively in picograms per milliliter or
as a percentage of control. LTB4 release (Figure 4a) was
induced only after a long incubation period. The maxi-
mum level rose significantly after 72 hours of treatment
(66.6 ± 3.7 pg/10
5 cells, P < 0.001).
5-LOX and FLAP are essential proteins responsible for
LTB4 synthesis. To determine whether augmented LTB4
production induced by HNE is related to 5-LOX and
FLAP synthesis, we further examined the effect of HNE
on their mRNA expression. As shown in Figure 4b, c,
our data disclosed that both FLAP and 5-LOX mRNA
expression rose significantly but differentially after incu-
bation in human OA chondrocytes. FLAP mRNA
expression occurred earlier, after 8 hours of incubation,
compared with 5-LOX (48 hours). Maximum FLAP and
5-LOX levels were 630% and 560% of control values,
respectively (P < 0.001).
Taken together, these results indicate that single treat-
ment with HNE in OA chondrocytes induced the shunt
from the production of PGE2 to LTB4 through COX-2
downregulation and 5-LOX and FLAP upregulation.
HNE-induced 5-LOX promoter activity
To more accurately identify whether HNE induced 5-
LOX at the transcription level, the 5-LOX promoter con-
struct with luciferase gene reporter was transiently trans-
fected into human OA chondrocytes, followed by
stimulation with single addition of 10 μMH N Et oa l l
wells excepted control for different time periods (n =4
independent experiments). Compared with unstimulated
cells, HNE induced 5-LOX gene promoter activity in
transfected chondrocytes. 5-LOX promoter activity
increased significantly by 310% and 580% after 48 and 72
hours of incubation, respectively (P < 0.05) (Figure 5).
These data indicate that HNE regulates 5-LOX mRNA
expression at the transcriptional level.
HNE-induced 5-LOX and FLAP expression is PGE2 and
TGF-b1 dependent
Further experiments were aimed at elucidating the role
of PGE2 and TGF-b1 production in HNE-induced 5-
LOX and FLAP expression in OA chondrocytes. Firstly,
cells were treated with 50 μM naproxen (a nonselective
COX inhibitor) for 1 hour followed by another
treatment for 24 or 72 hours with single addition of 10
μM HNE to all wells except the controls (n =4i n d e -
pendent experiments). HNE-induced changes in 5-LOX
and FLAP mRNA expression were evaluated as a per-
centage of control. Our real-time RT-PCR results
demonstrated that HNE induced FLAP expression after
24 hours of treatment (210% of control, P <0 . 0 0 1 )a n d
the level was even higher after 72 hours (315% of con-
trol, P < 0.001) (Figure 6a, b). FLAP activation by HNE
was abolished by naproxen, which prevents PGE2 pro-
duction. In contrast, HNE induced 5-LOX expression by
600% above control values (P < 0.001) (Figure 6d) only
after 72 hours of incubation. Incubation of cells with
naproxen, however, caused a consistent increase of 5-
LOX mRNA level by 330% and 570% of control values
(P < 0.001) after 24 and 72 hours of incubation, respec-
tively (Figure 6c, d). The addition of naproxen to HNE
had no additive effect on the 5-LOX mRNA level. All
these data suggest that PGE2 m a yp l a yac r i t i c a lr o l ei n
5-LOX and FLAP regulation by HNE.
Secondly, to determine whether TGF-b1p r o d u c t i o n
c o u l db ei n v o l v e di nH N E - i n d u c e d5 - L O Xa n dF L A P
expression, chondrocytes were treated or not with a sin-
gle addition of 10 μM HNE for 72 hours in the presence
or absence of 100 μg/ml TGF-b1 antibody. HNE-
induced changes in 5-LOX and FLAP mRNA expression
were evaluated as a percentage of control (untreated
cells). As illustrated in Figure 6e, the addition of anti-
TGF-b1 antibody to cultured cells attenuated HNE-
induced 5-LOX and FLAP by 40% (both P < 0.05). In
another experiment, the determination of TGF-b1b y
ELISA in the culture media from HNE-treated chondro-
cytes showed a significant increase in TGF-b1 levels in
comparison with untreated cells (control), and reached
210, 288 and 201 pg/ml after 24, 48, and 72 hours of
incubation, respectively (Figure 6f) (n = 5 independent
experiments, P < 0.05, P < 0.01 and P < 0.05).
Collectively, our results indicate that HNE-induced 5-
LOX and FLAP requires PGE2 and TGF-b1 production.
Discussion
HNE, a product of lipid peroxidation, has been identi-
fied as a modulator of signal transduction, gene tran-
scription and protein modification [21]. Our previous
study demonstrated that the level of HNE is significantly
higher in synovial fluids and in chondrocytes of OA
patients compared with normal subjects. HNE induces
cartilage degradation by transcriptional and post-tran-
scriptional changes of type II collagen and MMP-13 in
OA [18]. Recently, HNE was found to be an inflamma-
tory factor that stimulates the production of proinflam-
matory mediators, including PGE2, but its role in the
pathology of joint and inflammatory diseases remains
unclear. In the present study, we investigated the effects
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Figure 4 Hydroxynonenal-induced leukotriene B4 biosynthesis and 5-lipoxygenase and 5-lipoxygenase-activating protein expression
in human osteoarthritis chondrocytes. Cells were treated with single addition of 10 μM 4-hydroxynonenal for different incubation time
periods, as indicated above. (a) Leukotriene B4 (LTB4) production was evaluated by enzyme immunoassay commercial kit. (b) 5-lipoxygenase-
activating protein (FLAP) and (c) 5-lipoxygenase (5-LOX) mRNA expression was measured by real-time RT-PCR. Data are means ± standard errors
of the mean, n = 5, expressed as percentages of untreated cells. Student’s unpaired t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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Page 9 of 15of HNE on COX-2/mPGES-1 and 5-LOX pathways reg-
ulation in human OA chondrocytes. COX-2/mPGES-1
and 5-LOX are primary proteins in the synthesis of
PGE2 and LTB4, respectively.
In the present study, we observed that single treat-
ment of OA chondrocytes with 10 μM HNE induced
PGE2 release as well as COX-2 and mPGES-1 expres-
sion, which plateaued at 8 hours of incubation before
declining at 16 and 24 hours, respectively. These data
are in concordance with our previously reported COX-2
findings [20] and are supported by other investigations
indicating that HNE is a potent inducer of COX-2 and
PGE2 release in various cell lines, such as rat liver
epithelial RL34 cells and the RAW264.7 macrophage
cell line [29-31]. Interestingly, when HNE was main-
tained for 14 hours in cultured chondrocytes, through
repeated treatments at intervals of 2 hours, the aldehyde
induced both COX-2 and mPGES-1 expression up to 24
hours and consequently abolished their decrease. It has
been shown that the maintaining of HNE levels at 1 μM
through repetitive treatments regulated cell proliferation
and differentiation [32]. Our observations support the
view that decreased COX-2 and mPGES-1 expression is
attributed to HNE depletion via its metabolism in chon-
drocytes. Mammalian cells have developed multiple
enzymatic pathways for HNE detoxification. The best
characterized of these enzymes include glutathione S-
transferases, aldehyde dehydrogenase, and alcohol dehy-
drogenase [33]. The half-life of HNE in cells was esti-
mated to be ~1 hour [34]. On the contrary, we do not
exclude the possibility that the increase of COX-2 and
mPGES-1 expression up to 24 hours may coincide with
the inflammatory resolution. As demonstrated by Gilroy
and colleagues [35], COX-2 plays a role as a proinflam-
matory factor in the early phase of inflammation. During
the late phase, however, this enzyme regulates resolution
of acute inflammation by generating an alternate set of
prostaglandins, such as the cyclopentenone family.
Since mPGES-1 regulation by HNE has not yet been
reported, we extended our investigation to determine
whether changes in mRNA levels may be ascribed to
alterations in promoter activity by transiently transfect-
ing chondrocytes with human mPGES-1 promoter-luci-
ferase reporter genes. The treatment of transfected cells
with single addition of 10 μM HNE to cultures led to a
time-dependent increment of mPGES-1 promoter activ-
ity. These data are consistent with the regulation of
mPGES-1 expression by HNE at the transcription level.
Emerging evidence has disclosed that the transcriptional
induction of mPGES-1 is primarily controlled by Egr-1
through two Egr-1 binding motifs identified in the prox-
imal promoter region of mPGES-1 [36,37]. Numerous
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Page 11 of 15cytokines and growth factors are known to upregulate
mPGES-1 production via Egr-1 activation [38]. We
hypothesized that the induction of Egr-1 activity by
HNE could be the mechanism by which HNE exerts its
stimulatory effect on mPGES-1 transcription. In trans-
fected cells, HNE evoked the activation of a synthetic
luciferase reporter construct containing three tandem
repeats of Egr-1 motif. Our western blot data demon-
strated that 10 μM HNE heightened Egr-1 protein
expression in a time-dependent manner. Collectively,
these data suggest the involvement of this transcription
factor in HNE-induced transcriptional activity of the
mPGES-1 promoter in OA chondrocytes. Further
experiments are needed, however, to confirm the direct
implication of this transcription factor in HNE-induced
mPGES-1.
Thereafter, we explored 5-LOX and FLAP regulation
in human OA chondrocytes by HNE, examined the rela-
tive involvement of these two proteins in LTB4 produc-
tion, and studied the factors that might be responsible
for enhanced LTB4 production in these cells incubated
for long periods. Our data indicated that 5-LOX and
FLAP upregulation by HNE occurred, at least in part, at
the transcription level, as determined by real-time quan-
titative RT-PCR and transient transfection experiments.
HNE-induced 5-LOX and FLAP gene activation is dif-
ferentially time dependent. FLAP expression is activated
earlier than 5-LOX, which occurs only after 48 hours of
HNE stimulation. These results are consistent with a
previous report of Martel-Pelletier and colleagues show-
ing that 5-LOX expression is activated after that of
FLAP, leading to the late increase of LTB4 production
[28]. The FLAP mRNA level was significantly enhanced
after a short period (20 hours) of treatment with TGF-
b1 or 1,25-dihydroxyvitamin D3 alone or combined,
whereas the 5-LOX mRNA level rose only after 72
hours [28]. These authors postulated that the reason for
the late increment of 5-LOX mRNA may be that TGF-
b1 induces only 5-LOX mRNA accumulation and not
true upregulation of gene expression per se. Heightened
LTB4 production upon HNE stimulation occurred 48
hours after the beginning of stimulation, coinciding with
the time at which the 5-LOX mRNA level was elevated,
and FLAP gene expression remained high. These data
confirm that LTB4 production is dependent on the regu-
lation of both 5-LOX and FLAP. Other studies, however,
have demonstrated that the increase in LTB4 production
was mainly related to upregulation of the FLAP gene
[39] or to a combination of an increment in the activity
and/or expression of 5-LOX [40,41].
Several investigations have shown that 5-LOX and
FLAP expression is regulated by PGE2 [28,42]. Our
results put this observation in evidence. PGE2 inhibition
regulates 5-LOX and FLAP expression differentially.
Using the nonspecific inhibitor of COX, naproxen, we
abolished HNE-induced FLAP expression in OA chon-
drocytes after short or long periods of incubation. In
contrast, naproxen induced 5-LOX expression after
short or long stimulation time periods. The combination
of naproxen with HNE, however, had no additive effect
on 5-LOX mRNA expression. Significant advances have
been made in understanding the role of PGE2 in the
metabolism of articular tissues. PGE2 has been found
not only to be involved in inflammatory responses but
may also regulate the effects of other inflammatory
mediators. More pharmaceutical companies therefore
focus on mPGES-1 to treat arthritis because of its indu-
cible form and functional linkage with COX-2 [38].
Current therapies to treat OA are limited to reducing
the pain in affected joints by with either nonselective
nonsteroidal anti-inflammatory drugs or selective COX-
2 agents. The production of both PGE2 and LTB4
requires AA; therefore, one of the pathways is used
favorably, depending on the condition. Long-term COX
inhibition causes the switch from COX to the 5-LOX
pathway. This is observed in OA patients treated with
COX-2 inhibitors [43]. In our study, we also demon-
strated that lower PGE2 production favors the 5-LOX
pathway and LTB4 synthesis in HNE-treated OA chon-
drocytes. Leukotrienes have greater potential in the
inflammatory process, however, and may be more harm-
ful than PGE2 in various tissues due to their chemotac-
tic properties [44]. For this reason, drugs that can
inhibit both COX and lipoxygenase have attracted phar-
maceutical attention in the treatment of inflammatory
diseases. Tepoxalin and licofelone (ML3000) have been
identified to exert this function [45,46]. Today, licofe-
lone is in phase III clinical development. Licofelone not
only lowers PGE2 and LTB4 production, but can also
modify abnormal bone remodeling in OA; thus, it was
thought to be useful in treating OA [46].
In addition to the involvement of PGE2 in HNE-
i n d u c e d5 - L O Xa n dF L A P ,w ef o u n dd a t as u p p o r t i n g
t h er o l eo fT G F - b1 in this process. Our observations
showed that HNE evoked TGF-b1 synthesis and that
TGF-b1 neutralization by anti-TGF-b1 antibody attenu-
ated HNE-induced 5-LOX and FLAP after 72 hours of
incubation. These results suggest that 5-LOX and FLAP
regulation by HNE is partially mediated via TGF-b1
production. Leonarduzzi and colleagues were the first to
demonstrate that HNE stimulated TGF-b1p r o d u c t i o n
[47]. Furthermore, a number of reports support the role
of TGF-b1 in 5-LOX and FLAP expression through
smad3/4 activation [13,28,40].
Conclusions
Our data provide new evidence for the inflammatory
role of HNE, an oxidative stress-related product, in the
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Page 12 of 15physiopathology of OA. As illustrated in Figure 7, our
findings suggest that COX-2 and mPGES-1 downregula-
tion is attributed to HNE depletion and may be respon-
sible for the switch from COX-2 to 5-LOX and FLAP
pathways. Both PGE2 and TGF-b1 are involved in the
regulation of 5-LOX and FLAP by HNE in OA chondro-
cytes. In this context, a drug that inhibits HNE produc-
tion may be beneficial to attenuate inflammation in the
treatment of OA and inflammatory diseases.
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